期刊文献+

乙型肝炎肝细胞内HBcAg表达模式与肝组织炎症及血清学指标的关系 被引量:4

下载PDF
导出
摘要 目的探讨乙型肝炎患者肝细胞内乙型肝炎核心抗原(hepatitis B core antigen,HBcAg)表达模式与肝组织炎症分级、血清乙型肝炎病毒(hepatitis B virus,HBV)DNA含量以及ALT、AST酶活性的关系。方法收集乙型肝炎肝穿刺石蜡包埋组织标本89例,切片后分别行HE染色及免疫组化PV 6000法染色,并在光镜下观察、判定肝组织炎症分级和肝细胞内HBcAg的表达模式,同期应用荧光定量PCR法和速率法测定各患者的血清HBV DNA含量和ALT、AST酶活性。结果 (1)HBcAg浆型及浆型优势表达组的肝组织炎症程度高于核型及核型优势表达组(H=19.884,P=0.0002);(2)89例乙型肝炎患者血清HBV DNA含量平均值依次为:肝细胞内HBcAg核型表达组为(16.63±3.39)IU/ml、核型优势表达组为(14.92±3.85)IU/ml、浆型优势表达组为(12.14±3.20)IU/ml和浆型组为(10.91±3.64)IU/ml,其中浆型、浆型优势表达组分别与核型、核型优势表达组相比,差异有统计学意义(F=12.66,P=0.000 1);(3)肝细胞内HBcAg浆型或浆型优势表达组的血清ALT、AST酶活性高于核型或核型优势表达组(ALT:F=8.73,P=0.000 1;AST:F=4.26,P=0.007 4)。结论肝细胞内HBcAg呈浆型或浆型优势表达的乙型肝炎患者,其肝组织炎症分级和血清ALT、AST酶活性均较高,但血清HBV DNA含量较低。
出处 《临床与实验病理学杂志》 CAS CSCD 北大核心 2014年第6期686-688,共3页 Chinese Journal of Clinical and Experimental Pathology
基金 深圳市科技计划(医疗卫生类)(20103133 201202060)
  • 相关文献

参考文献11

二级参考文献71

共引文献14041

同被引文献34

  • 1Qing He,Qi-yuan Tang,Xiao-hua Le,De-liang Lv,Xiang-mei Zhang,Fei-jian Ao,Yi-min Tang,Shan Huang,John Nunnari,Gui-lin Yang.The Relationship between Intrahepatic Distribution of Hepatitis B Virus Core Antigen and Serum ALT, HBV DNA Levels and HBeAg Status[J].国际感染病学(电子版),2012,1(2):84-90. 被引量:4
  • 2许良中,杨文涛.免疫组织化学反应结果的判断标准[J].中国癌症杂志,1996,6(4):229-231. 被引量:1367
  • 3向光明,钟森,赵川,邓存良,史晓玲,周陶友,唐红.肝细胞癌患者血清乙型肝炎病毒X区及前S/S区基因变异特点[J].中华肝脏病杂志,2007,15(2):146-148. 被引量:5
  • 4Chiu YC, Liao SF, Wu JF, et al. Factors affecting the natural decay of hepatitis B surface antigen in children with chronic hepatitis B virus infection during long-term follow-up[J]. J Pediatr, 2014, 165(4): 767-772.
  • 5Pancher M, D6sir6 N, Ngo Y, et al. Coexistence of circulating HBsAg and anti-HBs antibodies in chronic hepatitis B carriers is not a simple analytical artifact and does not influence HBsAg quantification[J]. J Clin, 2015.62: 32-37.
  • 6YANG F Q, YU Y Y, WANG G Q, et al. A pilot ran- domized controlled trial of dual-plasmid HBV DNA vaccine mediated by in vivo electroporation in chronic hepatitis B patients under lamivudine chemotherapy [J]. J Viral Hepat, 2012, 19 .. 581-- 593.
  • 7PAWEOWSKA M, HALOTA W, SMUKALSKA E, et al. HBV DNA suppression during entecavir treat- ment in previously treated children with chronic hepati- tis B[J]. Eur J Clin Microbiol Infect Dis, 2012, 31, 571--574.
  • 8PRADEEP K S, MEDHI S, ASIM M, et al. Evalua- tion of adefovir lamivudine in chronic hepatitis B. correlation with HBV viral kinetic, hepatic-necro in- flammation fibrosis[J]. Indian J Med Res, 2011, 133:50--56.
  • 9FUNG ], SETO W K, LAI C L, et al. Profiles of HBV DNA in a large population of Chinese patients with chronic hepatitis B: Implications for antivira] therapy [J]. J Hepatol, 2011, 54:195--200.
  • 10SANAI F M, HELMY A, BZEIZI K I, et al. Discrimi- nant value of serum HBV DNA levels as predictors oI liver fibrosis in chronic hepatitis B[J]. J Viral Hepat, 2011, 18..e217-e225.

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部